The humoral immune response induced by
ISCOM-matrix (Immuno Stimulating COMplex-Matrix)-adjuvanted equine influenza virus (EIV)
vaccine is well documented in horses.
ISCOM-matrix adjuvanted
vaccines against
human influenza are strong inducers of cell-mediated immunity (CMI), including T cell proliferation and virus-specific cytotoxic T cell. In the horse, the CMI response to equine
influenza vaccination is less well characterised. An
ISCOM-based
vaccine has been shown to induce
interferon gamma (IFN-γ) synthesis, a CMI marker, in the horse, but this has not been shown for the
ISCOM-matrix
vaccine, which is a different formulation. The objective of this study was to measure EIV-specific IFN-γ synthesis after vaccination with an
ISCOM-matrix-adjuvanted EIV
vaccine. Equilis Prequenza is a commercialised inactivated EIV
vaccine containing purified haemagglutinin (HA) and
neuraminidase (NA) subunits adjuvanted with
ISCOM-matrix. Six
influenza-naïve Welsh mountain ponies were vaccinated twice with Equilis Prequenza at an interval of four weeks. Six control ponies received a placebo of physiological water. EIV-specific IFN-γ synthesis by peripheral blood lymphocytes and the antibody response to a panel of representative EIV isolates were measured prior to and after both
injections. Immunisation with the
ISCOM-matrix-based EIV
vaccine stimulated significant EIV-specific IFN-γ synthesis and EIV-specific single radial
haemolysis (SRH) antibody. In conclusion, EIV
vaccine adjuvanted with
ISCOM-matrix stimulates both antibody and a cellular immune response in the horse.